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Abstract
Expression of the tumor suppressor deleted in liver cancer-1 (DLC-1) is lost in non-small cell lung
(NSCLC) and other human carcinomas, and ectopic DLC-1 expression dramatically reduces
proliferation and tumorigenicity. DLC-1 is a multidomain protein that includes a Rho GTPase
Activating Protein (RhoGAP) domain which has been hypothesized to be the basis of its tumor
suppressive actions. To address the importance of the RhoGAP function of DLC-1 in tumor
suppression, we performed biochemical and biological studies evaluating DLC-1 in NSCLC. Full
length DLC-1 exhibited strong GAP activity for RhoA as well as RhoB and RhoC, but only very
limited activity for Cdc42 in vitro. In contrast, the isolated RhoGAP domain showed 5- to 20-fold
enhanced activity for RhoA, RhoB, RhoC and Cdc42. DLC-1 protein expression was absent in six
of nine NSCLC cell lines. Restoration of DLC-1 expression in DLC-1-deficient NSCLC cell lines
reduced RhoA activity, and experiments with a RhoA biosensor demonstrated that DLC-1
dramatically reduces RhoA activity at the leading edge of cellular protrusions. Furthermore, DLC-1
expression in NSCLC cell lines impaired both anchorage-dependent and -independent growth, as
well as invasion in vitro. Surprisingly, we found that the anti-tumor activity of DLC-1 was due to
both RhoGAP-dependent and -independent activities. Unlike the rat homologue p122RhoGAP,
DLC-1 was not capable of activating the phospholipid hydrolysis activity of phospholipase C-δ1.
Combined, these studies provide information on the mechanism of DLC-1 function and regulation,
and further support the role of DLC-1 tumor suppression in NSCLC.
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INTRODUCTION
DLC-1 (deleted in liver cancer-1) was identified originally as a gene whose expression was
lost in hepatocellular carcinomas (HCC). Subsequent studies found loss of DLC-1 gene
expression in liver, breast, colon, gastric, prostate, cervical, esophageal and other cancers
[1-5]. The downregulation of DLC-1 expression is particularly dramatic in non-small cell lung
*Corresponding Author: Channing J. Der, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center,
CB# 7295, Chapel Hill, NC 27599-7295. Phone: (919) 962-1057; Fax: (919) 966-0162; E-mail: E-mail: channing_der@med.unc.edu.
NIH Public Access
Author Manuscript
Mol Carcinog. Author manuscript; available in PMC 2009 May 10.
Published in final edited form as:













carcinomas (NSCLC); DLC-1 transcription was significantly reduced or lost in 95% (20/21)
of primary tumors and 58% (11/19) of NSCLC cell lines [6]. Ectopic restoration of DLC-1
expression in DLC-1-deficient NSCLC, HCC, breast and esophageal cancer cell lines resulted
in reduced growth in vitro and tumorigenicity and metastasis in vivo, supporting the role of
DLC-1 as a tumor suppressor [2,6-10].
DLC-1 is a 122 kDa multidomain protein that consists of an N-terminal SAM domain, a C-
terminal START domain, and an internal RhoGAP domain (Fig. 1A). The RhoGAP domain
is a conserved catalytic domain found in GTPase activating proteins for members of the Rho
family of small GTPases (RhoGAPs) [11]. SAM domains (~70 amino acids) are putative
protein interaction modules [12] and START domains (~120 amino acids) are lipid-binding
domains found in proteins that transfer lipids between organelles [13]. The roles of the SAM
and START domains in DLC-1 function have not been determined.
Rho GTPases comprise a major branch of the Ras superfamily of small GTPases, with RhoA,
Rac1 and Cdc42 the most intensely studied [14,15]. Like Ras, Rho GTPases function as binary
switches that cycle between active, GTP-bound and inactive, GDP-bound forms. In normal
cells, the Rho GDP/GTP cycle is tightly regulated. Extracellular stimulus-mediated activation
of Rho GTPases is facilitated by guanine nucleotide exchange factors (RhoGEFs) that promote
formation of Rho-GTP. Rho-GTP preferentially binds and regulates multiple downstream
effectors that in turn regulate cytoplasmic signaling networks that control actin cytoskeletal
organization, cell cycle progression, gene expression, cell movement and polarity, and
intracellular vesicular transport [16]. RhoGAPs negatively regulate GTPase function by
accelerating the weak intrinsic GTP hydrolysis activity of the GTPase, promoting formation
of the inactive, GDP-bound form. Whereas a variety of mechanisms that regulate RhoGEFs
have been identified [17], the regulation of RhoGAPs remains poorly understood.
In vitro analyses of rat (p122-RhoGAP) and human DLC-1 demonstrated that DLC-1 exhibits
robust GAP activity for RhoA [18,19]. Similarly, in vivo analyses showed that ectopic
expression of rat DLC-1 caused cell rounding and disruption of actin stress fibers, activities
consistent with inhibition of RhoA [20]. While DLC-1 [19] and the related DLC-2 protein
[21,22] have been reported to have weak or no in vitro activity for Cdc42 and Rac1, it has not
been determined whether DLC-1 functions as a GAP for the structurally and biochemically-
related, yet biologically-divergent, RhoB and RhoC GTPases [23,24].
Like Ras, the aberrant activation of Rho family GTPases has also been associated with cancer
progression and growth [25]. However, whereas mutational activation of Ras is prevalent in
human cancers, mutation of Rho GTPases has not been observed in human cancers. Instead,
aberrant Rho GTPase activity has been found in human cancers as a result of the altered
expression and/or function of Rho GTPases or their regulators. Of the diversity of mechanisms
that have been found, perhaps the most frequent and widespread involves the loss of DLC-1
expression in a variety of human cancers. By analogy to the loss of expression of the NF1 and
TSC2 tumor suppressors, that function as GAPs for Ras and the Ras-like GTPase Rheb [26],
the tumor suppressive functions of DLC-1 have been hypothesized to be due to its RhoGAP
activity. However, the significance of the RhoGAP activity to DLC-1-mediated tumor
suppression remains unclear. Since DLC-1 has been described to exhibit other functions, such
as the activation of phospholipase C delta (PLCδ) by the rat DLC-1 homologue, p122RhoGAP
[18], DLC-1 anti-tumor activity may be due to non-RhoGAP activities.
Because the importance of the RhoGAP function of DLC-1 in tumor suppression has not been
determined, we initiated studies to evaluate the biochemical and biological activity of DLC-1
in NSCLC. Our observations expand the Rho GTPase targets of DLC-1 and suggest that
intramolecular regulation may be limiting the activity of the full length protein. Furthermore,
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we demonstrate that, while DLC-1 expression reduces RhoA activity, the anti-tumor activity
of DLC-1 is reliant on both RhoGAP-dependent and - independent activities. Combined, our
observations expand our understanding of DLC-1 function and regulation, and further support
the role of DLC-1 as a tumor suppressor in NSCLC.
MATERIALS AND METHODS
DLC-1 Expression Plasmids
The cDNA sequence encoding human DLC-1 (nucleotides 321-3596 of accession #
NM_006094) was amplified through PCR of human embryonic kidney 293-T cDNA and
cloned into the pEGFP-N1 (Clontech) vector. Site directed mutagenesis was utilized to change
nucleotides 2472-2473 from GA to CG, creating the cDNA sequence encoding the DLC-1
(R718E) missense mutant. The following primer sequences were used: primer-1, 5'-
CATGCTGAAGCAGTATTTTGAAGATCTTCCTGAGCCACTA-3' and primer-2, 5'-
TAGTGGCTCAGGAAGATCTTCAAAATACTGCTTCAGCATG-3'. For NSCLC
expression experiments, the wild type and mutant DLC-1 cDNA sequences were subcloned
into the BamHI site of the pBabe-puro retroviral expression vector. Oligonucleotide-directed
PCR mutagenesis was utilized to restore the stop codon in the last triplet and add a 3' SalI site.
Parallel manipulations were performed with a pEGFP-N1 vector encoding DLC-1(R718E) to
generate the pBabe-puro DLC-1(R718E) expression construct. For transient assays, the open
reading frame of DLC-1 was excised from pBabe-puro DLC-1 with BamHI and Sal1, and
subcloned into the BamHI-Sal1 sites of pcDNA 3.1+ (Invitrogen). The pcDNA3.1+ vectors for
PLC-β2, Rac3 G12V, and PLC-δ1 were obtained from the Guthrie cDNA Resource Center.
For the RhoA biosensor experiments, the cDNA sequence encoding the mCherry fluorescent
protein tag was PCR-amplified and subcloned into the Kpn1-BamHI sites of pcDNA DLC-1
to create the coding sequence for the mCherry DLC-1 fusion protein.
For expression of recombinant protein, cDNA sequences for DLC-1, DLC-1(R718E), and the
isolated DLC-1 RhoGAP domain were subcloned into the pGEX-5X-3 (GE Healthcare)
bacterial expression vector for expression of glutathione S-transferase (GST)-DLC-1 fusion
proteins. All plasmid cDNA coding sequences were sequence verified before use. pGEX
plasmids for expression of GST fusions of wild type human RhoA, RhoB, RhoC, Rac1 and
Cdc42 have been described previously [27,28].
Bacterial Protein Expression and Purification
Plasmids encoding GST-fusion proteins of DLC-1 and Rho GTPases were transformed into
the BL-21 E. coli strain. GST-DLC-1 (full length DLC-1, DLC-1(R718E), and DLC-1 GAP
expression was induced with 100 μM isopropyl-B-D-1-thiogalactopyranoside (IPTG) for 16
h at room temperature. GST fusion proteins of human RhoA, RhoB, and RhoC were induced
with 250 μM IPTG for 16 h at room temperature. Rac1 and Cdc42 were induced with 1 mM
IPTG for 3 h at 37°C. GST-fusion proteins were purified by glutathione Sepharose 4B
chromatography, and the purity of soluble proteins was assessed by Coomassie staining.
Purified proteins were quantified by the method of Bradford [29].
Single Turnover GTP Hydrolysis Assay
The in vitro GAP activity of DLC-1 was measured with a fluorescence-based technique [30].
This assay utilizes a fluorophore-conjugated phosphate binding protein (MDCC-PBP) that
dramatically increases in fluorescence upon binding phosphate. Purified glutathione-agarose
bead bound-Rho GTPases were preloaded with GTP in an exchange buffer (20 mM Tris, 50
mM NaCl, 200 mM ammonium sulfate, 10 mM EDTA, and 0.5 mM GTP) for 1 min at 37°C.
Following elution, single turnover hydrolysis assays were performed with 15 μM MDCC-PBP
and 2 μM GTPase in a buffer containing 20 mM Tris, 50 mM NaCl, and 1 mM MgCl2. Assays
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were initiated with addition of 0.30 μM DLC-1, and a SpectraMAX Gemini (Molecular
Devices) spectrofluorimeter was used to measure increases in fluorescence (λex = 425 nm and
λem = 465 nm), reflecting increases in Pi production from GTP hydrolysis.
Cell Culture and Generation of Stable Cell Lines
293-T and Cos-7 cells were maintained in Dulbecco's modification of Eagle's medium
supplemented with 10% fetal bovine serum (FBS; Hyclone). NSCLC cells were obtained from
the ATCC (Rockville, MD) and grown in RPMI-1640 supplemented with 10% FBS. To
generate NSCLC cell lines stably-expressing ectopic DLC-1 proteins, infectious virus of the
pBabe-puro vectors encoding DLC-1 or DLC-1(R718E) was generated and used to infect the
NSCLC cell lines. After selection in growth medium containing 1.0 μg/mL puromycin,
multiple drug resistant colonies were pooled together to establish mass populations stably
expressing each DLC-1 protein. Multiple, independently established stable cell lines (<3
passages) were used for all analyses, to evaluate reproducibility and to minimize secondary
consequences of prolonged maintenance of cell lines ectopically expressing growth
suppressing proteins.
RhoA Activity Assay
A GST-fusion of the Rho-GTP binding domain (RBD) of Rhotekin (amino acids 7-89), an
effector of RhoA, RhoB, and RhoC, was used in pull down assays to detect expression of
activated RhoA-GTP as we have described previously [31]. Total and GST-RBD-precipitated
lysate samples were subjected to SDS-PAGE and analyzed by western blot analysis using anti-
RhoA antibody (Santa Cruz Biotechnology). Exogenous DLC-1 expression was confirmed by
probing the total lysate samples with the monoclonal anti-DLC-1 antibody (612020, BD
Biosciences).
RhoA Biosensor Experiments
The genetically encoded RhoA biosensor based on CFP/YFP intramolecular fluorescence
resonance energy transfer (FRET) was described previously [32]. Briefly, the sensor is
comprised of the Rhotekin-RBD which specifically binds to RhoA-GTP, followed by cyan
fluorescent protein, an unstructured linker of optimized length, a pH-insensitive variant of
yellow fluorescent protein Citrine YFP, and the full length RhoA. Upon GTP loading and
activation of RhoA, the binding domain within the biosensor binds to the activated RhoA and
changes the relative orientation of CFP and Citrine YFP to affect FRET. By monitoring the
ratio of donor and acceptor fluorescence emission, spatio-temporal dynamics of RhoA
activation can be studied.
MEF/3T3 cells stably expressing RhoA biosensor under tetracycline-off regulator [32] were
induced to express the RhoA biosensor by removal of doxycyclin and replating at 4 × 104 cells
in a 10 cm diameter tissue culture dish. Twenty four h after induction, cells were detached and
replated at 1 × 105 cells in a 10 cm tissue culture dish, and transfected with 1 μg of mCherry-
DLC-1 DNA using Fugene 6 (Roche Diagnostics, Indianapolis, IN). Twenty four h post
transfection, cells were replated on glass coverslips coated with fibronectin (10 μg/ml) (Sigma,
St. Louis, MO) at 4 × 104 cells per coverslip and allowed to adhere and spread for 5 h prior to
imaging experiments.
Cells were imaged in Ham's F-12K medium without phenol red (Biosource), with 2% FBS, 10
mM HEPES buffer and 10 μg/ml Oxy-Fluor reagent supplemented with 5mM dl-lactate
(Oxyrase Inc.), in a heated Atto-fluor chamber (Molecular Probes). Images were obtained using
a Zeiss 40× 1.3 NA EC-Plan NeoFluar DIC lens on a Zeiss Axiovert 100TV microscope, a
CoolsnapES charged coupled device camera (Roper Scientific), and Metamorph software
(Universal Imaging). For ratio imaging of the RhoA biosensor, the following filters were used
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(Chroma Technology): CFP: D436/20, D470/40; FRET: D436/20, HQ535/30; YFP:
HQ500/20, HQ535/30. mCherry-DLC-1 was imaged using HQ580/30, HQ630/40. A “Custom
Quad” dichroic mirror was custom manufactured by Chroma Company for compatibility with
all of these filters. Filterwheels were used to change the filters in the excitation and emission
light paths (Ludl Electronic Products, Hawthorne, NY). Cells were illuminated with a 200 W
Hg/Xe arc lamp (Optiquip, Highland Mills, NY) through a 36% neutral density filter. At each
time point, autofocus was performed in DIC followed by DIC image acquisition, the three
fluorescence images were recorded with the following exposure times: CFP (800ms), FRET
(400ms) and mCherry-DLC-1 (500ms) at binning 2×2.
Metamorph version 7.1.2 (Universal Imaging) was used to perform the image processing and
data analysis. All images were flat-field corrected and background subtracted. FRET and CFP
images were then carefully aligned either manually or automatically [33] to ascertain correct
pixel-to-pixel registration. The FRET image, because it had the largest signal-to-noise ratio
and therefore provided the best distinction between the cell and the background, was intensity
thresholded to generate a binary mask with a value of zero outside the cell and a value of one
inside the cell. FRET and CFP images were multiplied by this binary mask to set areas outside
the cell uniformly to zero to minimize noise and other artefacts. The masked FRET image was
divided by the masked CFP image to yield a ratio reflecting RhoA activation throughout the
cell. A linear pseudocolor lookup table was applied and the ratio values were normalized to
the lower scale value. In every data set, CFP and FRET images were carefully inspected to
verify that all portions used to create the ratio image had a high enough signal/noise ratio. This
was especially important in thin parts of the cell where fluorescence was low. In time-lapse
experiments, CFP and YFP bleached at different rates. The ratio was corrected for bleaching
using a published method [34]. Because ruffles and cell edges can move rapidly, it was
important to exclude motion artefacts; we routinely reversed the order of FRET and CFP
acquisition to ascertain that motion artefacts were negligible, or used fixed cells (data not
shown).
Growth Transformation and Invasion Assays
Mass populations of drug-resistant NCI-H23 and A549 cells stably-infected with the empty
pBabe-puro vector, or encoding DLC-1 proteins, were analyzed in soft agar assays as we have
described previously [35,36]. In triplicate, 2 × 104 NCI-H23 or 104 A549 cells were trypsinized
and resuspended in growth medium containing 0.4% agar. Cultures were maintained at 37°C
for 21 days, at which point viable colonies were stained with the MTT (3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) viability stain and photographed. The
number of proliferating colonies (>10 cells) was quantified by counting the number of colonies
in five representative fields of view within each plate.
Invasion in vitro was measured by using the Matrigel transwell assay with 8.0 μm pore Growth
Factor Reduced Matrigel Invasion Chambers (BD Biosciences) according to the manufacturer's
protocol. NCI-H23 cells were dissociated with TrypLE Express (Invitrogen), and 7.5 × 103
cells resuspended in serum-free RPMI-1640 containing 1% bovine serum albumen were seeded
into the upper chamber. RPMI-1640 containing 3% FBS (chemoattractant) was added to the
well beneath the chamber. After 22 h at 37°C, non-invaders were removed, and invading cells
were fixed, stained, photographed, and quantified. Five fields were counted for each chamber,
and the total number of cells counted per chamber was used for calculating the average number
of invading cells. The relative number of invading cells was determined by arbitrarily assigning
the cells transfected with empty vector a value of 1.0. The two-tailed Student's t test was used
to quantify statistical differences between experimental groups for the soft agar and Matrigel
assays. Results are expressed as mean ± SD.
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The ability of DLC-1 to promote phoshoinositide hydrolysis activity of PLC-δ1 was quantified
by measuring the accumulation of 3[H]inositol phosphates as previously described [37].
Briefly, Cos-7 cells were plated in 12-well culture dishes transfected with the indicated DNA
expression vector using FuGENE 6 transfection reagent (Roche) according to the
manufacturer's protocol. Empty-vector DNA was used as necessary to maintain a constant total
amount of DNA per well. Twenty-four h after transfection, the medium was replaced with
inositol- and serum-free DMEM containing 1 uCi/well [myo-3H]inositol (American
Radiolabeled Chemicals, St. Louis, MO). Phospholipase activity was quantified 12 h after
labeling by incubation in inositol-free DMEM containing 10 mM LiCl. After approximately
60 min, ice-cold 50 mM formic acid was added to stop the reaction. 150 mM ammonium
hydroxide was used to neutralize the reaction, and the accumulation of [3H]inositol phosphates
was quantified by Dowex chromatography as described previously [37].
RESULTS
DLC-1 Stimulates RhoA, RhoB, and RhoC GTP Hydrolysis Activity In Vitro
Previous studies demonstrated clearly that DLC-1 has potent GAP activity for RhoA in vitro.
Whether DLC-1 is also a GAP for the biochemically-related, yet biologically-distinct, RhoB
and RhoC proteins is not known. In contrast to RhoA, conflicting observations have been made
for the ability of DLC-1 to serve as a GAP for Cdc42 and Rac1. Therefore, we evaluated the
ability of DLC-1 to accelerate the GTP hydrolysis of RhoA, RhoB, RhoC, Cdc42, and Rac1.
For these analyses we purified bacterially-expressed DLC-1 (Fig. 1A) and GST fusion proteins
of human RhoA, RhoB, RhoC, Cdc42 and Rac1. Using a fluorescence-based technique that
measures single turnover GTP hydrolysis [30], we measured the ability of full length DLC-1
to stimulate the intrinsic GTP hydrolysis activity of these GTPases. In agreement with previous
studies, we found that DLC-1 had robust activity on RhoA in vitro. Furthermore, DLC-1 also
had strong GAP activity on both RhoB and RhoC (Fig. 1B - D). To aid our studies on the
contribution of the RhoGAP function to DLC-1 tumor suppression, we introduced a missense
mutation in the conserved arginine-718 residue critical for RhoGAP catalytic activity [38]. We
found that DLC-1(R718E) was completely impaired in stimulating the intrinsic hydrolysis
activity of GTP-loaded RhoA, RhoB, and RhoC in vitro (Fig. 1B - D).
Intramolecular Regulation of DLC-1 Impairs its GAP Activity
Our previous observations with another RhoGAP (p190RhoGAP), which is also a GAP for
RhoA, RhoB, and RhoC, found that ectopic overexpression of p190RhoGAP caused significant
cell rounding [39]. In contrast, our initial observations found that ectopic overexpression of
DLC-1 did not cause significant cell rounding (data not shown). Therefore, we speculated that
full length DLC-1 may not be fully active. The RhoGAP domain of DLC-1 comprises only
146 residues (amino acids 655-801) of the full length, 1,091 residue protein. The presence of
significant N- and C-terminal flanking regions suggests that DLC-1 could be highly regulated,
possibly by intramolecular interactions with flanking sequences and domains. Therefore, we
expressed the isolated RhoGAP domain of DLC-1 (residues 609-878; designated DLC-1 GAP)
and compared the activity with full length DLC-1.
We determined that DLC-1 GAP was extremely robust on RhoA in vitro, accelerating the GTP
hydrolysis nearly 70-fold, or approximately 20-fold more than the activity seen with the full
length protein (Fig. 2A and B). DLC-1 GAP was also particularly robust on RhoB and RhoC,
accelerating the GTP hydrolysis 5- to 10-fold more than full-length DLC-1 (Fig. 2C - F). For
Cdc42, acceleration of intrinsic GTP hydrolysis increased from a modest 1.4-fold activity for
full length DLC-1 to 10-fold stimulation with DLC-1 GAP, corresponding to a 7-fold increase
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in RhoGAP activity (Fig. 2G and H). We also observed similar activities in cells, where
transient expression of DLC-1 RhoGAP, but not full length DLC-1, caused considerable cell
rounding (data not shown). Additionally, introduction of the R718E mutation into DLC-1
RhoGAP completely abolished this rounding activity, demonstrating that this mutation
abolished RhoGAP activity in vivo.
Interestingly, neither DLC-1 nor DLC-1 GAP displayed any activity towards Rac1 (Fig. 2I and
J). Our results contrast with observations made with the related DLC-2 protein [21]. The
isolated RhoGAP fragment of DLC-2 (80% identical) had altered substrate specificity, as it
was active on Cdc42 and Rac1, but not RhoA, whereas the full length DLC-2 was reported to
be robust towards RhoA and Cdc42, with mild activity on Rac1. Unlike DLC-2, the flanking
regions of the DLC-1 GAP domain do not affect Rho GTPase substrate specificity.
Dlc-1 Protein Expression is Lost in Non-Small Cell Lung Cancers
Yuan et al. employed RT-PCR analyses and demonstrated that the DLC-1 transcript is lost in
both primary tumors (20/21, 95%) and NSCLC cell lines (11/19, 58%) [6]. We utilized a
DLC-1-specific monoclonal antibody to evaluate DLC-1 protein expression in a panel of
NSCLC cell lines, and determined that expression of DLC-1 was lost in 6 of 9 (67%) NSCLC
cell lines (Fig. 3). This pattern of DLC-1 protein expression correlated with previous analyses
of DLC-1 transcription for 5 of the 6 lines that were evaluated in both studies [6]. The only
exception was the NCI-H2228 cell line, which was reported to be positive for DLC-1 mRNA
but we determined was negative for DLC-1 protein expression. However, we utilized RT-PCR
analyses and determined that our strain of NCI-H2228 cells was deficient for DLC-1 mRNA
expression (data not shown), suggesting that the discrepancy is due to variations in cell line
history. Hence, loss of DLC-1 protein expression correlated absolutely with the absence of
DLC-1 gene transcription. Three NSCLC cell lines (A549, NCI-H23, and NCI-358) that we
found to be DLC-1 negative for both the transcript and protein analysis were chosen for further
biological studies.
DLC-1 Expression Modulates Rho GTPase Activity In Vivo
Whether DLC-1 expression can modulate RhoA activity in vivo has not been demonstrated.
To address this question, we ectopically restored DLC-1 expression in two DLC-1-deficient
NSCLC cell lines (NCI-H23 and NCI-H358). For all of the ectopic DLC-1 expression studies,
the level of expression ranged from comparable to ~3-fold greater than endogenous DLC-1
(NCI-H1703 cells). Restoration of wild type, but not R718E, DLC-1 expression significantly
reduced the level of RhoA-GTP in both NCI-H23 and NCI-H358 cell lines (Fig. 3B). These
results suggest that loss of DLC-1 will cause increased Rho GTPase activity.
DLC-1 Expression Reduces Rho GTPase Activity at the Edge of Cellular Protrusions
In addition to using pull down analyses to demonstrate that DLC-1 can reduce total cellular
RhoA-GTP levels, we utilized a RhoA biosensor to quantify spatially distinct changes in RhoA
activity. MEFs stably expressing a RhoA biosensor were transfected with an mCherry DLC-1
vector, and fluorescence resonance energy transfer (FRET) analysis was performed to quantify
RhoA activity, as previously described [32]. Interestingly, DLC-1 expression resulted in a
preferential reduction of RhoA activity at the leading edge of cellular protrusions (Fig. 4). To
verify that the DLC-1 expression was not limited to this region in the cell, we analyzed
mCherry-DLC-1 expression and, consistent with published reports [40,41], DLC-1 was
localized to focal adhesions throughout the cells (Fig. 4C). These results indicate that there are
some DLC-1 localizations for which RhoGAP activity is more activated, and that the RhoGAP
activity of DLC-1 plays a role in leading edge dynamics.
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DLC-1 Displays both GAP-Dependent and -Independent Tumor Suppression
To assess the importance of GAP activity to DLC-1 mediated tumor suppression, we utilized
mass populations of NCI-H23 and A549 cells stably expressing ectopic wild type DLC-1 or
DLC-1(R718E). Interestingly, using a clonogenic growth assay to monitor the proliferation of
retrovirus-infected cells, we observed that cells infected with either the wild type or the R718E
mutant showed a much reduced frequency of drug-resistant colonies than was seen with the
empty pBabe-puro retrovirus-infected cells (data not shown). The DLC-1-mediated reduction
in clonogenic growth was similar to what had been reported previously [6], while the DLC-1
(R718E)-mediated reduction provided an initial suggestion that DLC-1 possesses RhoGAP-
independent growth inhibitory activity.
To extend previous biological studies, we analyzed the impact of DLC-1 expression on the
anchorage-independent growth of two DLC-1-deficient NSCLC cell lines that grow well in
soft agar. We observed that DLC-1 caused an approximately 60% reduction in colony forming
efficiency, as well as colony size, in soft agar for both NCI-H23 and A549 NSCLC cells (Fig.
5). Surprisingly, expression of the GAP-dead DLC-1(R718E) also significantly inhibited
anchorage-independent growth, though to a lesser extent (~40% colony reduction) than seen
with the wild type protein.
We also examined the impact of DLC-1 expression upon NSCLC cell migration and invasion.
In NCI-H23 and A549 NSCLC cells, expression of DLC-1 did not alter cellular motility in
wound healing assays (data not shown). However, DLC-1 expression did reduce invasion in
Matrigel assays by 50% in NCI-H23 cells (Fig. 6). The GAP-dead DLC-1(R718E) mutant
reduced invasion by approximately 25%, though this decrease was not statistically significant
(P = 0.18). Likewise, the DLC-1-mediated reduction in A549 invasiveness (~30%) was not
statistically significant (data not shown). These results, together with the anchorage-
independence assays, suggest that DLC-1 uses both GAP-dependent and -independent
mechanisms to suppress NSCLC growth and invasion.
DLC-1 does not stimulate the phospholipids hydrolysis activity of PLC-δ1
To investigate a possible mechanism of GAP-independent activity, we investigated the ability
of DLC-1 to activate PLC-δ1, as has been reported for the rat homologue p122RhoGAP.
Activation of PLC was quantified by measuring the accumulation of [3H]inositol phosphates,
as we have described previously [37]. Co-transfection of an activated Rac3 mutant (Rac3
G12V) along with the PLC-β2 isozyme resulted in a dramatic increase in [3H]inositol
phosphates (Fig. 7A), demonstrating the sensitivity of the cell-based system for detecting
changes in PLC activity. Surprisingly, co-transfection of DLC-1 with PLC-δ1 did not result in
an increase in [3H]inositol phosphate accumulation (Fig. 7B), suggesting that, unlike rat
DLC-1, human DLC-1 does not activate the phospholipid hydrolysis activity of PLC-δ1.
DISCUSSION
Expression DLC-1, a member of the RhoGAP family of negative regulators of Rho GTPases,
is lost in NSCLC and other human cancers [6]. Ectopic restoration of DLC-1 expression in
DLC-1-deficient tumor cell lines reduced growth in vitro and tumorigenicity and metastatic
growth in vivo, supporting a tumor suppressor function for DLC-1 [7-9]. By analogy to the
NF1 and TSC2 tumor suppressors, which function as GAPs for Ras and Rheb small GTPases
[26], respectively, the loss of DLC-1 is hypothesized to promote oncogenesis by causing
hyperactivation of Rho GTPases. However, the mechanistic basis of DLC-1's tumor
suppression has remained largely unknown. Unexpectedly, we found that DLC-1 growth
suppression may be mediated by both RhoGAP-dependent and -independent functions.
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Previous studies demonstrated that DLC-1 is a potent GAP for RhoA in vitro [19]. We have
verified and extended these observations, and showed that DLC-1 is a potent GAP for the
structurally and biochemically-related RhoB and RhoC proteins. Though RhoA, RhoB and
RhoC form a closely related subgroup (~90% amino acid identity) of the Rho GTPase family,
they have strikingly different biological functions [23,24]. For example, Hynes and colleagues
found that increased expression and activity of RhoC but not RhoA was important for
melanoma invasion and metastasis [42]. Mercurio and colleagues found that RhoA impeded
but RhoC stimulated breast cancer cell invasion [43]. However, unlike RhoA and RhoC, RhoB
is commonly under expressed in cancers, and this GTPase suppresses various aspects of cancer
progression [44]. Thus, it is not clear how the loss of DLC-1 GAP activity on this negative
regulator of cancer progression could contribute to tumor suppression. A recent report
demonstrated that RhoB is frequently lost in NSCLCs [45], and thus it is possible that the
potential effects of DLC-1 acting as a GAP on RhoB are limited by the reduced expression of
RhoB in DLC-1 positive tumors. Nonetheless, our finding of DLC-1 GAP activity on RhoB
and RhoC expands the known targets of DLC-1, increasing the potential mechanisms by which
DLC-1 functions.
The isolated DLC-1 GAP domain was 5- to 20-fold more active than the full length protein in
vitro, responsible for limiting its activity. We also found that the isolated RhoGAP domain,
but not full length DLC-1, caused potent cell rounding, indicating that the isolated RhoGAP
fragment is a constitutively activated DLC-1 in vivo. Our further analyses of N-terminally-
deleted variants of DLC-1 determined that deletion of the SAM domain alone increased GAP
activity in vitro and was sufficient for constitutive RhoGAP activity in vivo (manuscript in
preparation). Thus, our present studies are focused on determining a possible mechanism where
the SAM domain functions as an intramolecular negative regulator of DLC-1 RhoGAP
catalytic activity.
The impact of DLC-1 on Rho-GTP levels in vivo had not been addressed directly.
Microinjection of rat DLC-1 caused a reduction in actin stress fibers and inhibited
lysophosphatidic acid-stimulated stress fiber formation, phenotypes suggestive of reduced
RhoA-GTP levels [20]. Likewise, Wong et al. recently demonstrated that DLC-1 inhibited
stress fiber formation in HCC cells [46]. We addressed this directly and showed that ectopic
restoration of wild type, but not RhoGAP-deficient, DLC-1 expression in DLC-1-deficient
NSCLC cells reduced RhoA-GTP levels, demonstrating that DLC-1 functions as a GAP for
RhoA in vivo. Thus, loss of DLC-1 expression is expected to result in persistent activation of
Rho GTPases in NSCLCs. Our future studies will determine if elevated RhoA-GTP levels are
associated with DLC-1-deficiency in NSCLC cell lines and patient tumors.
We also utilized a RhoA biosensor to demonstrate that DLC-1 expression significantly reduces
RhoA activity, specifically at the edge of cellular protrusions. MEFs expressing DLC-1 had
reduced motility and formed fewer protrusions (data not shown). It is likely that the ability of
DLC-1 to reduce RhoA activity at the edge of cells contributes to the reduced migratory ability
of DLC-1 expressing cells, and may contribute to DLC-1's ability to suppress invasion and
metastasis [7].
Our studies determined that DLC-1 growth suppression is mediated by both RhoGAP-
dependent and -independent functions. We found that exogenous expression of DLC-1 in the
DLC-1 deficient NCI-H23 and A549 NSCLC cells resulted in an approximately 60% decrease
in anchorage-independent growth. Surprisingly, the GAP-deficient DLC-1(R718E) mutant still
suppressed anchorage-independent growth very significantly (~40% reduction). Similar trends
were observed in Matrigel invasion assays, in which DLC-1 suppressed invasion of H23 cells
~50%, whereas DLC-1(R718E) reduced invasion by about 25%. These results suggest that the
RhoGAP activity of DLC-1 is only partially responsible for its anti-tumor activity. Our results
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contrast with observations from a previous study investigating the significance of GAP activity
to DLC-1-mediated growth inhibition. In their clonogenic growth analyses, ectopic DLC-1
expression reduced the number of HCC colonies grown on culture dishes following transfection
and puromycin selection, whereas their putative GAP-deficient variant of DLC-1 (K714E) had
no effect on colony formation [46]. Our different observations are not entirely surprising since
Rho GTPases have been implicated in many facets of the tumorigenic and malignant
phenotype, but with cell type differences.
The ability of the rat homologue of DLC-1, p122RhoGAP, to activate PLC-δ is the only other
known catalytic activity associated with DLC-1. To investigate the RhoGAP-independent anti-
tumor functions of DLC-1, we conducted experiments to quantify the ability of DLC-1 to
activate PLC-δ1. Surprisingly, we found that DLC-1 did not activate the phospholipid
hydrolysis activity of PLC-δ1, suggesting that the protein has distinct functions from rat
DLC-1, p122RhoGAP. DLC-1 interaction with caveolin-1 [47] or tensin2 [41] remains
interesting possibilities for GAP-independent functions for tumor suppression, since there is
evidence for the function of both of these proteins in oncogenesis.
In summary, our studies provide information on the mechanisms by which DLC-1 functions
as a tumor suppressor in NSCLC. In particular, we determined that DLC-1 expression will alter
the level of Rho GTPase activity in NSCLCs and that DLC-1 growth suppression involves
both Rho-dependent and Rho-independent mechanisms. Lastly, our studies suggest that DLC-1
will be regulated by posttranslational mechanisms. Identifying the interacting partners of
DLC-1 is essential to developing a more comprehensive understanding of the mechanism of
regulation of DLC-1 function.
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DLC-1 is a RhoGAP. (A) Schematic of the structure of wild type and mutant human DLC-1
proteins used in this study. (B) DLC-1 is a RhoGAP for RhoA, (C) RhoB, and (D) RhoC. The
GTP hydrolysis rate of recombinant GST fusion proteins of RhoA, RhoB, and RhoC was
measured in the presence and absence of 0.30 μM DLC-1. GAP activity of a missense mutant
of DLC-1, with substitution of a conserved arginine residue in the RhoGAP catalytic domain
(DLC-1(R718E)), was also determined. The small GTPases were preloaded with GTP, and
incubated with a fluorescently-labeled phosphate binding protein (PBP) which undergoes a
dramatic increase in fluorescence upon binding inorganic phosphate released from GTP
hydrolysis. Real time GTP hydrolysis was monitored by measuring the increases in
fluorescence, which directly correlated with GTP hydrolysis. Data shown are representative
of two independent experiments.
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The isolated RhoGAP domain shows greatly enhanced catalytic activity for RhoA, RhoB,
RhoC and Cdc42. Recombinant full length and an isolated RhoGAP catalytic domain fragment
(amino acids 609-878) of DLC-1 were expressed and purified for analysis of in vitro GAP
activity. Real time GTP hydrolysis was measured with a fluorescently labeled PBP, as
described in Fig. 1, for GST fusion proteins of wild type (A, B) RhoA, (C, D) RhoB, (E, F)
RhoC, (G, H) Cdc42, and (I, J) Rac1. Data shown are representative of three independent
experiments.
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DLC-1 protein expression is lost in NSCLC cell lines and associated with increased RhoA-
GTP formation. (A) DLC-1 protein expression is lost in some NSCLCs. Lysates from nine
NSCLC cell lines were resolved by SDS-PAGE and transferred to a PVDF membrane. A
monoclonal antibody was used for western blot analysis of DLC-1 expression (612020; BD
Biosciences). A parallel blot for β-actin was done to ensure equivalent loading of total cell
lysate protein. (B) Ectopic expression of wild type but not mutant DLC-1 is associated with a
reduction of RhoA-GTP activity in NSCLCs. Mass populations of two NSCLC cell lines,
deficient in endogenous DLC-1 protein expression, were established via infection with the
pBabe-puro retrovirus vector encoding wild type full length DLC-1 or the GAP-dead mutant,
DLC-1(R718E). RhoA-GTP levels were assessed by incubating lysates with GST-Rhotekin-
RBD that was precoupled to glutathione-sepharose beads. Precipitated and total lysates (4%
loading control) were analyzed by western blotting with anti-RhoA and -DLC-1 antibodies.
Data shown are representative of two independent experiments.
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DLC-1 expression reduces RhoA activity at the leading edge of cellular protrusions. MEFs
stably expressing a RhoA biosensor were transiently-transfected with mCherry-tagged DLC-1
and plated on fibronectin. (A) Time-lapse images of RhoA activity during cellular protrusion.
Regions of intense RhoA activity are shown in red. Scale bar, 10 μm. (B) Quantification of
RhoA activity at varying distances from the edge of the cell. RhoA activity was quantified
along 120 line-scans drawn perpendicular to the edge of 8 mCherry control cells and 103 line-
scans perpendicular to the edge of 8 mCherry DLC-1 cells. Data points represent the average
± SD (C) mCherry DLC-1 is expressed at focal adhesions in the MEFs. Expression of the
mCherry fluorescence is shown for representative control and DLC-1 cells.
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Ectopic re-expression of DLC-1 impairs NSCLC anchorage-independent growth. NCI-H23
and A549 NSCLC cells stably-infected with the pBabepuro vector encoding DLC-1 or DLC-1
(R718E) were evaluated for colony formation in soft agar and the number of proliferating viable
colonies was quantitated after 21 days. (A) Viable colonies were stained with MTT and
photographed. (B) The total number of colonies (> 10 cells) within five representative fields
of view was quantified. Data shown are the average ± SD of triplicate wells and are
representative of three independent experiments. *, significant at P ≤ 0.005 vs. vector; †,
significant at P < 0.01 vs. vector and vs. wild type DLC-1.
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DLC-1 reduces NSCLC invasion in vitro. NCI-H23 cells stably-infected with the pBabe-puro
vector encoding DLC-1 or DLC-1(R718E) were assessed for invasion through Matrigel. Cells
were dissociated, resuspended in serum-free growth media containing 1% BSA, and incubated
for 22 h at 37°C in a Matrigel invasion chamber; the lower well contained growth medium
supplemented with 3% FCS. Non-invaders were removed, and the chambers were fixed and
stained. (A) Invading cells were photographed under 10X magnification. (B) Quantification
of invading cells. Data shown are the mean ± SD of triplicate wells and are representative of
two independent experiments. *, significant at P ≤; 0.01 vs. vector.
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DLC-1 does not stimulate phosphoinositide hydrolysis activity of PLC-δ1. Cos-7 cells were
transiently transfected with vectors encoding various PLC isoforms and known or putative
activators. Intracellular inositol phosphate accumulation was quantified as described in
Methods. (A) PLC-β2 phospholipid hydrolysis activity is activated by constitutively activated
Rac3. To verify the assay conditions, we coexpressed PLC-β2 with Rac3 G12V, an established
activator of PLC-β2, and quantified [3H]inositol phosphate accumulation. (B) PLC-δ1 activity
is not stimulated by DLC-1. Zero toδ100 ng of expression vector encoding PLC-δ1 was co-
transfected with 0, 25, 50, 100, or 200 ng of DNA encoding human DLC-1, and the
accumulation of [3H]inositol phosphates was quantified. Data shown are the mean ± SD of
triplicate determinations and are representative of results obtained in two independent
experiments.
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